

Exhibit I

State of California ex rel. Ven-A-Care of the Florida Keys, Inc.
v. Abbott Laboratories, Inc., et al., Master Civil Action No. 01-12257-PBS,
Subcategory Case No. 06-11337

Exhibit to the December 21, 2009 Declaration of Christopher C. Palermo in Support
of Defendants Mylan Inc. and Mylan Pharmaceuticals Inc.'s. Opposition to Plaintiffs' Motion for Partial Summary
Judgment

Mylan Laboratories, Inc. 30(b)(6) - Harry A. Korman

November 26, 2007

Canonsburg, PA

Page 1

1 IN THE UNITED STATES DISTRICT COURT

2 DISTRICT OF MASSACHUSETTS

3 - - - - -

4 -----X

5 THE COMMONWEALTH)

6 OF MASSACHUSETTS,)

7 Plaintiff,) Civil Action

8 -vs-) No. 03-11865-PBS

9 MYLAN LABORATORIES, INC.,)

10 IVAX CORPORATION, WARRICK) November 26, 2007

11 PHARMACEUTICALS CORPORATION,) Monday, 9:00 a.m.

12 WATSON PHARMACEUTICALS, INC.,)

13 SCHEIN PHARMACEUTICAL, INC.,) Canonsburg, PA

14 TEVA PHARMACEUTICALS USA, INC.,)

15 PAR PHARMACEUTICAL, INC.,)

16 ETHEX CORPORATION, PUREPAC)

17 PHARMACEUTICAL CO., and)

18 ROXANE LABORATORIES, INC.,)

19 Defendants.)

20 -----X

21 VIDEOTAPE 30(B)(6) DEPOSITION OF MYLAN LABORATORIES,

22 INC. by HARRY A. KORMAN

Mylan Laboratories, Inc. 30(b)(6) - Harry A. Korman

November 26, 2007

Canonsburg, PA

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p style="text-align: right;">Page 2</p> <p>1 VIDEOTAPE 30(B)(6) DEPOSITION OF MYLAN LABORATORIES, 2 INC. by HARRY A. KORMAN 3 4 DATE: November 26, 2007 5 Monday, 9:00 a.m. 6 LOCATION: Hilton Garden Inn 7 1000 Corporate Drive 8 Canonsburg, PA 9 TAKEN BY: Plaintiff 10 REPORTED BY: Nina Warren Biehler 11 Notary Public 12 13 VIDEOTAPE DEPOSITION OF HARRY A. KORMAN, 14 a witness, called by the Plaintiff for examination, 15 in accordance with the Federal Rules of Civil 16 Procedure, taken by and before Nina Warren Biehler, 17 a Court Reporter and Notary Public in and for the 18 Commonwealth of Pennsylvania, at the Westmoreland 19 Room of the Hilton Garden Inn, Pittsburgh, 20 Pennsylvania, on Monday, November 26, 2007, 21 commencing at 9:15 a.m. 22</p> | <p style="text-align: right;">Page 4</p> <p style="text-align: center;">I N D E X</p> <p>1 2 3 WITNESS: MYLAN LABORATORIES, INC. PAGE 4 (HARRY A. KORMAN) 5 Examination by Mr. Mullin..... 006 6 7 8 E X H I B I T S 9 10 (No Deposition Exhibits were marked) 11 12 13 14 15 16 17 18 19 20 21 22</p> |
| <p style="text-align: right;">Page 3</p> <p>1 APPEARANCES: 2 3 FOR THE PLAINTIFF: 4 Peter A. Mullin, Esq. 5 Robert C. Molvar, Esq. 6 Assistant Attorneys General 7 Medicaid Fraud Control Unit 8 100 Cambridge Street 9 Boston, MA 02114 10 P 617-727-2200 / F 617-727-2008 11 robert.molvar@ago.state.ma.us 12 13 FOR THE DEFENDANT MYLAN LABORATORIES, INC.: 14 William A. Escobar, Esq. 15 Kelley Drye & Warren, LLP 16 101 Park Avenue 17 New York, New York 10178 18 P 212-808-7771 / F 212-808-7897 19 Wescobar@kelleydrye.com 20 21 ALSO PRESENT: 22 Matt Martin, Videotape Technician</p> | <p style="text-align: right;">Page 5</p> <p style="text-align: center;">P R O C E E D I N G S</p> <p>1 2 3 VIDEOTAPE TECHNICIAN: Good morning, my 4 name is Matthew Martin. I am the videographer, 5 I'm here from AKF Court Reporting and Video Tech 6 Services. 7 Today's date is November 26th, 2007. 8 The time right now is 9:15 a.m., that's indicated 9 on the screen. 10 We're here to take the video deposition 11 of Howard Korman in the case of Commonwealth of 12 Massachusetts versus Mylan Labs. We are at 1000 13 Corporate Drive, Canonsburg, Pennsylvania 15317. 14 This case is being heard in the U.S. District 15 Court of Massachusetts, Civil Action Number 03- 16 11865. 17 Would counsel please identify 18 themselves and who they represent. 19 MR. MULLIN: Peter Mullin and Robert 20 Molvar, assistant attorney generals for the 21 Commonwealth of Massachusetts. 22 MR. ESCOBAR: William Escobar, of</p> |

2 (Pages 2 to 5)

Mylan Laboratories, Inc. 30(b)(6) - Harry A. Korman

November 26, 2007

Canonsburg, PA

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p style="text-align: right;">Page 14</p> <p>1 informed me I'd be a 30(B)(6). 2 Q. What counsel have you met with? 3 A. Bill and Brian, one of our additional 4 counsel. 5 Q. Brian Cuthbertson? 6 A. Yes. 7 Q. Anyone else? 8 A. No. 9 Q. And when did you meet with Bill and 10 Brian? 11 A. Last week, I believe. 12 Q. On one or more than one occasion? 13 A. Last week was one occasion. 14 Q. And prior to that did you meet in 15 connection with appearing as the 30(B)(6) 16 witness, some time prior to last week? 17 A. I'm not sure we discussed the 30(B)(6) 18 deposition prior to that. 19 Q. Other than yourself, Mr. Cuthbertson 20 and Mr. Escobar, was anyone else present at the 21 meeting? 22 A. Yes, an attorney by the name of Jill</p> | <p style="text-align: right;">Page 16</p> <p>1 regard to appearing here today as a 30(B)(6) 2 witness? 3 A. To that effect, no. 4 Q. Have you searched for any documents or 5 records in preparation for your testimony here 6 today? 7 A. No, I have not. 8 Q. And have you reviewed any documents or 9 records in preparation for your testimony here 10 today? 11 A. With counsel, yes. 12 Q. What documents or records have you 13 reviewed in preparation for your testimony as the 14 Mylan 30(B)(6) witness? 15 A. Just the one document that had Mr. 16 Roman's testimony with regards to the question I 17 was going to be answering. 18 Q. Other than the transcript of Mr. 19 Roman's testimony, have you reviewed any other 20 documents or records in preparation for your 21 testimony here today as a Mylan corporate 22 representative?</p> |
| <p style="text-align: right;">Page 15</p> <p>1 Ondos. I don't know if she was there during any 2 of the discussion on the 30(B)(6). 3 Q. What's Jill's last name? 4 A. Ondos. 5 Q. Can you spell that for me? 6 A. O-N-D-O-S. 7 Q. Anyone else present at the meeting? 8 A. No. 9 Q. Have you reviewed any prior transcripts 10 in preparation for this deposition? 11 A. I did see a transcript, yes. 12 Q. What transcript did you review? 13 A. I don't know what the title of the 14 transcript would have been, it was -- 15 Q. Whose testimony was it? 16 A. It was Mr. Roman's. 17 Q. And was it at the deposition that he 18 gave in this case as representative of Mylan 19 Corporation? 20 A. I believe it was. 21 Q. Have you spoken with any of the sales 22 or marketing executives of the company with</p> | <p style="text-align: right;">Page 17</p> <p>1 MR. ESCOBAR: Objection to the form. 2 THE WITNESS: In terms of this 3 testimony, no. 4 BY MR. MULLIN: 5 Q. During the period 1998 to 2003 did 6 Mylan report pricing information to First Data 7 Bank regarding Mylan's pharmaceutical products? 8 A. I believe we did. 9 Q. And did that include average wholesale 10 price or AWP prices? 11 A. Yes, I believe we did. 12 Q. And did that include wholesale 13 acquisition cost or WAC prices? 14 A. Yes, I believe it did. 15 Q. Was one of Mylan's purposes in 16 reporting these prices to First Data Bank so that 17 these prices could be used by others for 18 reimbursement purposes? 19 A. No. 20 Q. What was Mylan's purposes in reporting 21 those prices to First Data Bank? 22 A. To make the marketplace aware that the</p> |

5 (Pages 14 to 17)

Mylan Laboratories, Inc. 30(b)(6) - Harry A. Korman

November 26, 2007

Canonsburg, PA

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p style="text-align: right;">Page 18</p> <p>1 products were being marketed and were available 2 for sale. 3 Q. Was Mylan aware that others used those 4 prices for reimbursement purposes? 5 MR. ESCOBAR: Now, let me just note an 6 objection, because I think you're now going 7 beyond the judge's order and you're going to 8 areas that were already asked and answered. 9 MR. MULLIN: Your objection is noted. 10 You may answer. 11 THE WITNESS: Yeah, I don't think Mylan 12 really knows exactly what the reimbursers do with 13 regards to the pricing that we offer. 14 BY MR. MULLIN: 15 Q. Speaking as a representative of Mylan 16 Corporation, during the period 1998 to 2003 was 17 Mylan aware that others used AWP and WAC prices 18 for reimbursement purposes? 19 MR. ESCOBAR: Same objection. 20 THE WITNESS: You know, I -- I think 21 the company knows the products are marketed and 22 that's part of what we publish.</p> | <p style="text-align: right;">Page 20</p> <p>1 not to answer you have the option to do that. 2 MR. ESCOBAR: Well, Mr. Mullin, we're 3 here for a specific -- you agree with me that the 4 judge ordered the 30(B)(6) witness to appear and 5 answer one specific question? Do you agree with 6 that? 7 MR. MULLIN: You may note your 8 objection. 9 MR. ESCOBAR: No, it's not a question 10 of an objection. We're here on a specific 11 question that we were ordered to prepare the 12 witness and to have a witness to answer, he has 13 done that directly. And now you're going back 14 through testimony that was already asked and 15 answered by the prior 30(B)(6) witness. So I 16 don't think it's either fair to us or to the 17 witness for you to do that. 18 If you can explain to me why you think 19 you're entitled to go through it again, then I'll 20 give that some thought, but you're not really 21 entitled to cover the same ground. 22 BY MR. MULLIN:</p> |
| <p style="text-align: right;">Page 19</p> <p>1 BY MR. MULLIN: 2 Q. That's not the question I've asked you, 3 sir. 4 I'm asking you to focus on the years 5 1998 to 2003 -- 6 MR. ESCOBAR: Mr. Mullin, you're going 7 over testimony that was already asked of the 8 witness. I believe the specific order by the 9 judge was to answer one specific question, which 10 you've now asked and it's been answered. That's 11 the question that he's here to testify about on 12 behalf of the company. 13 You did cover those exact questions 14 with Mr. Roman, so I don't see why you're -- 15 MR. MULLIN: Are you directing the 16 witness not to answer? 17 MR. ESCOBAR: Well, I want you to tell 18 me why you think you can go through questions 19 that you've already asked a witness. 20 MR. MULLIN: I have a question to pose. 21 I'll pose it, you can tell me -- your objection 22 will be noted. If you want to direct the witness</p> | <p style="text-align: right;">Page 21</p> <p>1 Q. Mr. Korman, during the period 1998 to 2 2003 was Mylan Corporation aware that the prices, 3 the AWP and WAC prices which it reported to 4 various price reporting services, including First 5 Data Bank, was used by others for reimbursement 6 purposes, yes or no? 7 MR. ESCOBAR: And you can answer that 8 question based on your knowledge, but you're not 9 a designee for that particular question. So if 10 you can answer that question based on your 11 general knowledge go ahead. 12 THE WITNESS: Do you want to repeat the 13 question? 14 BY MR. MULLIN: 15 Q. During the period '98 to 2003 was Mylan 16 aware that the prices it reported to First Data 17 Bank and other price reporting services, the AWP 18 prices and the WAC prices, were used by others 19 for reimbursement purposes? 20 MR. ESCOBAR: Same objections. 21 THE WITNESS: I think the company was 22 aware that they published the prices. If they're</p> |

6 (Pages 18 to 21)